Evidence map›Paper›PMID 38106622›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2023

Arginine Biosynthesis Pathway Found to Play a Key Role in the Neuroprotective Effect of Liu-Wei-Luo-Bi (LWLB) Granules in Diabetic db/db Mice with Peripheral Neuropathy Using an Untargeted Metabolomics Strategy.

Qiong Liu, Yafei Chen, Bo Wang, Yinying Chen, Bing Li, Shuang Guan, Kehe Du, Xiaoyang Liu, Yanan Yu, Jun Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qiong LiuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Yafei ChenInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Bo WangInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Yinying ChenGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Bing LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Shuang GuanInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Kehe DuiPhase Pharma Services, Beijing, People's Republic of China.
Xiaoyang LiuiPhase Pharma Services, Beijing, People's Republic of China.
Yanan YuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Jun LiuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Zhong WangInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNAstellas Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Liu-Wei-Luo-Bi (LWLB) granules was a Chinese compound prescription for treating diabetic peripheral neuropathy (DPN). The aim of this study was to investigate the effect of LWLB granules on diabetic mice with peripheral neuropathy and to elucidate the potential mechanism based on an untargeted metabolomics approach. Methods: One hundred forty db/db mice were randomly divided into seven groups: the Control group, DPN group, Mudan (MD) granules group, Epalrestat (Epa) group, and the LWLB low, medium, or high dose (LW-l, LW-m, or LW-h) group. After 12 weeks of treatment, body weight, blood glucose, mechanical pain threshold, motor conduction velocity (MCV), sensory conduction velocity (SCV), and Pathological Organization of the Sciatic and Caudal Nerves in mice were measured. Serum samples were collected for untargeted metabolomics analysis using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) and multivariate statistics. Disease-related pathways were screened out with function enrichment analyses of candidate biomarkers. Results: LWLB granules can improve the peripheral neuropathy of type 2 diabetic mice with peripheral nerve conduction disorders, mainly through significantly improving the nerve conduction velocity (P < 0.05) and lowering the mechanical pain threshold (P < 0.05). A total of 43 metabolites were identified as potential biomarkers related to the therapeutic effect of LWLB granules. Fifty, 4, and 26; 23, 4, and 22; and 24, 1, and 16 biomarkers were discovered in the LW-l, LW-m, and LW-h groups at the 4th, 6th, and 12th weeks, respectively. Five, three, seven, five, and four metabolic pathways were found in MD, Epa, LW-l, LW-m, and LW-h groups, respectively. The arginine biosynthesis pathway is the overlapping pathway in LW-l, LW-m, and LW-h groups. Conclusion: LWLB granules have an obvious neuroprotective effect on diabetic peripheral neuropathy, and the metabolism mechanism of LWLB is mainly related to the arginine biosynthesis pathway on diabetic db/db mice with peripheral neuropathy.

Indexed as

arginine biosynthesisdiabetic peripheral neuropathyLiu-Wei-Luo-Bi granulesTraditional Chinese Medicineuntargeted metabolomics

Identifiers

PMID38106622
PMCPMC10723181
OpenAlexW4389570024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.